Showing results (591-600 of 818) with videos related to

Sort By:
Pageof 82
Psychopharmacology|January 1, 1992
L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunctionK W Lange, T W Robbins, C D Marsden, et al.
Neuropharmacology|August 1, 1986
MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal areaA J Bradbury, B Costall, P G Jenner, et al.
Neuropharmacology|October 1, 1989
Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxinA Ueki, P N Chong, A Albanese, et al.
Neuroscience Letters|April 10, 1987
Modulation of the long-latency reflex to stretch by the supplementary motor area in humansJ P Dick, J C Rothwell, B L Day, et al.
Biochemical Pharmacology|August 1, 1985
Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the ratN M Rupniak, M D Hall, S Mann, et al.
European Journal of Pharmacology|January 12, 1993
Age-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosetsS Rose, M Nomoto, E A Jackson, et al.
Genomics|January 1, 1993
Evidence for locus heterogeneity in autosomal dominant torsion dystoniaF Ahmad, M B Davis, H M Waddy, et al.
Clinical Neuropharmacology|August 1, 1996
Botulinum toxin in the treatment of writer's crampN Turjanski, Z Pirtosek, J Quirk, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 1, 1994
Unusual focal dyskinesias: the ears, the shoulders, the back, and the abdomenJ N Caviness, A Gabellini, C S Kneebone, et al.
Psychopharmacology|February 1, 1995
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmosetK K Gnanalingham, D D Erol, A J Hunter, et al.
Pageof 82